Ashfield Advisory, part of UDG Healthcare plc, today announced the acquisition of PHMR Limited, a Market Access Consultancy and specialist in Health Econ
Ashfield Engage, a business unit of Ashfield, part of UDG Healthcare plc., today launches as an engagement and commercialization partner for the healthcare
The US FDA announced today that it has cleared two novel gene therapies for sickle cell disease: Vertex Pharmaceuticals' Casgevy and bluebird bio's Lyfgenia.
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio